News

Capillaroscopy May Help Earlier Detection of Systemic Sclerosis-Related Interstitial Lung Disease Cases

In a recent study entitled “Difficulties in diagnosis of systemic sclerosis-related interstitial lung disease”, researchers present a case-report of a Caucasian woman and highlight the difficulties in identifying and diagnosing systemic sclerosis-associated with interstitial lung disease. The study was published in the Respirology Case Reports…

RayVa Topical Treatment Safe and Effective in Phase 2a SCL-Related Raynaud’s Phenomenon Trial from Apricus

Top-line results from the Apricus Biosciences, Inc. Phase 2a clinical trial for RayVa™ topical treatment in patients with scleroderma-related Raynaud’s phenomenon indicate the treatment is safe and effective. Patients tolerated treatment and reported a noticeable change in the way their skin temperature responded to a cold challenge. There are…

Cytori’s Cell Therapy Offers Long-Term Benefits for Scleroderma Patients with Impaired Hand Function

Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an…

Corbus Pharmaceuticals Initiates Phase 2 Study Patient Enrollment of Resunab for Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. a clinical stage drug development company targeting chronic, rare, and serious inflammatory and fibrotic diseases with clear unmet needs, recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Systemic Sclerosis (Scleroderma) is a…